Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002908935 | SCV003254298 | uncertain significance | not provided | 2021-12-19 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The methionine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. This variant has not been reported in the literature in individuals affected with EPB41-related conditions. This variant is present in population databases (rs182542991, gnomAD 0.08%). This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 138 of the EPB41 protein (p.Val138Met). |
Ambry Genetics | RCV002908936 | SCV003689983 | uncertain significance | Inborn genetic diseases | 2021-10-29 | criteria provided, single submitter | clinical testing | The c.412G>A (p.V138M) alteration is located in exon 8 (coding exon 5) of the EPB41 gene. This alteration results from a G to A substitution at nucleotide position 412, causing the valine (V) at amino acid position 138 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003485797 | SCV004234701 | uncertain significance | Elliptocytosis 1 | 2023-02-13 | criteria provided, single submitter | clinical testing |